Pharmacology: Betahistine mesylate widens the precapillary sphincter, increasing blood circulation in the inner ear. Betahistine mesylate regulates capillary permeability in the inner ear, thereby eliminating endolymphatic hydrops. Betahistine mesylate also improves cerebral circulation and increases internal carotid artery blood flow.
Helps to relieve vertigo, dizziness, which is associated with balance disorders that occur in blood circulation disorders or Meniere's syndrome, Meniere's disease, and peripheral vertigo.
Mertigo tab: Adult: 1-2 tabs 3 times daily. The dose is adjusted according to patient's age and disease states.
Mertigo SR tab: Adult: 1 SR tab twice daily, taken after meal.
Patients with pheochromocytoma.
Mertigo SR tab: Patients with hypersensitivity to cetirizine, hydroxyzine or one component of the drug. Pregnancy and lactation.
Caution must be exercised when given to patients with peptic and/or gastric ulcer, history of gastrointestinal ulcers, active digestive ulcer, urticaria or rash and bronchial asthma.
Use in Pregnancy: Safety of use in pregnancy has not been established, thus Mertigo should only be given if the benefits outweigh the potential risks that may occur.
Nausea, vomiting, or other gastrointestinal disorders; Hypersensitivity, such as a rash on the skin may occur even in rare cases.
Gastrointestinal: Nausea, vomiting or other gastrointestinal disturbances.
Hypersensitivity Reactions: Skin rash (rare).
Store in the temperature 30°C. Keep away from sunlight.
N07CA01 - betahistine ; Belongs to the class of antivertigo preparations.
Mertigo tab 6 mg x 100's. Mertigo SR tab 12 mg x 10 x 10's.